ASCO 2019: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer

Both niraparib alone and the combination had meaningful activity in platinum-sensitive recurrent ovarian cancer. Compared to niraparib alone, the chemotherapy-free regimen of niraparib and bevacizumab significantly improved progression-free survival in women with platinum-sensitive recurrent ovarian cancer, regardless of homologous recombination-deficiency status and duration of chemotherapy-free-interval.

Hear Mansoor Raza Mirza present the new data.